Pular para o conteúdo

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

5 de agosto de 2026 · 19 min

Notas do episódio

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?


In this week’s episode of The Weekly Dose, I dig into Novo’s long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txt


We also break down Pfizer’s decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer’s remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly’s obesity-fueled rally and asking just how big this market can get.


In this episode:


00:00 Novo’s synthetic semaglutide problem

02:00 VoaFit sponsor message

03:30 The 16-month-old On The Pen receipt

05:00 Recombinant vs. synthetic semaglutide

07:00 Novo’s FDA, legal, and political strategy

09:00 Pfizer kills two obesity drugs

11:00 What happened to Metsera’s oral pipeline?

13:00 The GIP agonist vs. antagonist paradox

15:00 Why China matters to Pfizer and Novo

17:00 Could Novo eventually make synthetic semaglutide?

18:30 What comes next for Lilly, Novo, and Pfizer


The big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?


Comment below. I want to know where you land.


More obesity medicine news and analysis: OnThePen.com


All my links, socials, and resources: linktr.ee/manonthemounjaro


This episode is sponsored by VoaFit. Learn more at voafit.com/otp.


#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera

Todos os episódios de On The Pen GLP-1 News

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.